Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
Is the Rs 10,000 crore IPO jinx over ? LG India shares listing breaks 15-year old Coal India record
14/10/2025
The end of the American Century : New possibilities for a rising Asia
14/10/2025
Tata Investment Corp shares crash 90% in just one day ! Is that true ?
14/10/2025
Multi-cap strategy key for Samvat 2082 as valuations normalize : ICICI Pru Life CIO
14/10/2025
